Status:
COMPLETED
A Continuation Study to Assess the Effect of CellCept in Patients With Myasthenia Gravis.
Lead Sponsor:
Hoffmann-La Roche
Collaborating Sponsors:
Aspreva Pharmaceuticals
Conditions:
Myasthenia Gravis Generalised
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
This 2 arm study will provide optional continuation of double-blind treatment with CellCept or placebo, in patients with myasthenia gravis who have achieved good symptom control in study WX17798. Pati...
Eligibility Criteria
Inclusion
- subjects who have completed 36 weeks of treatment in study WX17798, and who have demonstrated good symptom control with a stable prednisone dose for the final 4 weeks of that study.
Exclusion
- regularly scheduled plasma exchange or intravenous immunoglobulin treatment;
- medical condition, adverse event or intolerance of double-blind treatment which would preclude continuation.
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 1 2007
Estimated Enrollment :
136 Patients enrolled
Trial Details
Trial ID
NCT00408213
Start Date
June 1 2004
End Date
September 1 2007
Last Update
May 23 2008
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Sun City, Arizona, United States, 85351
2
Sacramento, California, United States, 95817
3
Upland, Pennsylvania, United States, 19013
4
Bordeaux, France